Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders

About this update from Spectral Medical Inc

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the results of its Annual and Special Meeting of shareholders (the "Shareholders") held on June 8, 2026 (the "Meeting"). The Company confirms that all resolutions put forward in the Management Information Circular dated April 27, 2026 (the "Circular") to its Shareholders were approved. Results of the matters voted on at the Meeting are set out below.Election of Directors Spectral's seven director nominees were elected:NomineeVotes For (percent)Votes Withheld (percent)Jan D'Alvise98.51%1.49%Jun Hayakawa99.83%0.17%Chris Seto83.50%16.50%William Stevens99.61%0.39%Paul Walker94.28%5.72%David W. Feigal, Jr.99.41%0.59%Cristiano Franzi98.80%1.20%Appointment of AuditorsMNP LLP, Chartered Professional Accountants, was re-appointed as auditor of Spectral. Votes For: 99.96% Votes Withheld: 0.04%Adoption of Omnibus Long Term Incentive Plan A resolution approving the re-adoption of the Corporation’s omnibus long term incentive plan, as more particularly described in the Circular was passed. Votes For: 84.39% Votes Against: 15.61%Approval of Consolidation A special resolution authorizing the future amendment of the articles of the Company to consolidate all of the Company's issued and outstanding common shares (the "Shares"), on the basis of a consolidation ratio in the range of 1 post-consolidation Share for 5 pre-consolidation Shares to 1 post-consolidation Share for 10 pre-consolidation Shares to be selected by the board of directors of the Corporation (the "Board"), at such time as the Board so determines within 12 months of the date of the Meeting, was approved. Votes For: 87.63% Votes Against: 12.37%About Spectral Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s FDA cleared Endotoxin Activity Assay (EAA™), the clinically available test for endotoxin in blood. PMX is approved for therapeutic use in Japan and Europe, licensed by Health Canada, and has been used safely and effectively with over 360,000 units sold ...

View stock analysis, news, and events for Spectral Medical Inc